<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266706</url>
  </required_header>
  <id_info>
    <org_study_id>7625A-010</org_study_id>
    <secondary_id>CXA-PEDS-13-08</secondary_id>
    <secondary_id>2014-003485-24</secondary_id>
    <secondary_id>MK-7625A-010</secondary_id>
    <nct_id>NCT02266706</nct_id>
    <nct_alias>NCT02725216</nct_alias>
  </id_info>
  <brief_title>Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)</brief_title>
  <official_title>A Phase 1, Non-comparative, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Ceftolozane/Tazobactam in Pediatric Patients Receiving Standard of Care Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the pharmacokinetics, safety, and tolerability of a
      single intravenous dose of ceftolozane/tazobactam (MK-7625A) in pediatric participants. In
      each of the 6 age cohorts, an interim analysis of pharmacokinetics (PK) and safety data was
      conducted after approximately 3 participants had received the initially proposed dose. The
      interim analysis was to determine whether the initial dose was appropriate based on
      pre-defined criteria. If data from the interim analysis demonstrated that the initially
      proposed dose met the above criteria, enrollment was to continue with the same dose
      administered to approximately 3 additional participants of the same age range. However, if
      the interim analysis demonstrated that a new optimized dose was required, the new dose was to
      be administered to approximately 3 additional participants of the same age range.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2014</start_date>
  <completion_date type="Actual">June 15, 2017</completion_date>
  <primary_completion_date type="Actual">June 8, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Ceftolozane</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of Cmax of ceftolozane. Cmax is expressed as geometric least-squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Tazobactam</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of Cmax of tazobactam. Cmax is expressed as geometric least-squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Ceftolozane</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of Tmax of ceftolozane.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Tazobactam</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of Tmax of tazobactam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration at the Last Quantifiable Concentration (Clast) of Ceftolozane</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of Clast of ceftolozane. Clast is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration at the Last Quantifiable Concentration (Clast) of Tazobactam</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of Clast of tazobactam. Clast is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Last Sampling Point (Tlast) of Ceftolozane</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of Tlast of ceftolozane.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Last Sampling Point (Tlast) of Tazobactam</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of Tlast of tazobactam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUClast) of Ceftolozane</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of AUC from time zero to the last quantifiable concentration of ceftolozane. AUC0-last is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUClast) of Tazobactam</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of AUC from time zero to the last quantifiable concentration of tazobactam. AUC0-last is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUC0-inf) of Ceftolozane</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of AUC from time zero extrapolated to infinity of ceftolozane. AUC0-inf is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUC0-inf) of Tazobactam</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of AUC from time zero extrapolated to infinity of tazobactam. AUC0-inf is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half-life (t1/2) of Ceftolozane</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of t1/2 of ceftolozane. t1/2 is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half-life (t1/2) of Tazobactam</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of t1/2 of tazobactam. t1/2 is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Ceftolozane</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of Vss of ceftolozane. Vss is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Tazobactam</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of Vss of tazobactam. Vss is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Clearance (CL) of Ceftolozane</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of CL of ceftolozane. CL is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Clearance (CL) of Tazobactam</measure>
    <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
    <description>Blood was collected for the determination of CL of tazobactam. CL is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Adverse Events</measure>
    <time_frame>Up to Day 10</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued the Study Due to an Adverse Event</measure>
    <time_frame>Up to Day 10</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Proven or Suspected Gram-negative Bacterial Infection</condition>
  <condition>Peri-operative Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Cohort 1: ≥12 to &lt;18 years TOL/TAZ 1000/500 mg FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: ≥7 to &lt;12 years TOL/TAZ 18/9 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥7 to &lt;12 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: ≥2 to &lt;7 years TOL/TAZ 18/9 or 30/15 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥2 to &lt;7 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: ≥3 months to &lt;2 years TOL/TAZ 18/9 or 30/15 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥3 months to &lt;2 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: birth to &lt;3 months TOL/TAZ 20/10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 mg/kg was changed to TOL/TAZ 20/10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: birth to &lt;3 months TOL/TAZ 12/6 or 20/10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance =20 - 49 mL/min/1.73 m^2 received a single dose of TOL/TAZ 12/6 mg/kg as a 60-minute infusion on Day 1; participants with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 was changed to TOL/TAZ 20/10 mg/kg for participants with creatinine clearance ≥50 mL/min/1.73 m^2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/Tazobactam 1000/500 mg</intervention_name>
    <description>A fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.</description>
    <arm_group_label>Cohort 1: ≥12 to &lt;18 years TOL/TAZ 1000/500 mg FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/Tazobactam 30/15 mg/kg</intervention_name>
    <description>A FDC of 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam as a 60 minute infusion.</description>
    <arm_group_label>Cohort 3: ≥2 to &lt;7 years TOL/TAZ 18/9 or 30/15 mg/kg</arm_group_label>
    <arm_group_label>Cohort 4: ≥3 months to &lt;2 years TOL/TAZ 18/9 or 30/15 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/Tazobactam 20/10 mg/kg</intervention_name>
    <description>A FDC of 20 mg/kg of ceftolozane and 10 mg/kg of tazobactam as a 60 minute infusion.</description>
    <arm_group_label>Cohort 5: birth to &lt;3 months TOL/TAZ 20/10 mg/kg</arm_group_label>
    <arm_group_label>Cohort 6: birth to &lt;3 months TOL/TAZ 12/6 or 20/10 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/Tazobactam 18/9 mg/kg</intervention_name>
    <description>A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.</description>
    <arm_group_label>Cohort 2: ≥7 to &lt;12 years TOL/TAZ 18/9 mg/kg</arm_group_label>
    <arm_group_label>Cohort 3: ≥2 to &lt;7 years TOL/TAZ 18/9 or 30/15 mg/kg</arm_group_label>
    <arm_group_label>Cohort 4: ≥3 months to &lt;2 years TOL/TAZ 18/9 or 30/15 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/Tazobactam 12/6 mg/kg</intervention_name>
    <description>A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.</description>
    <arm_group_label>Cohort 6: birth to &lt;3 months TOL/TAZ 12/6 or 20/10 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Males or non-pregnant females from birth to &lt;18 years of age

          2. Receiving standard of care antibiotic therapy for suspected or diagnosed Gram-negative
             infection or for peri-operative prophylaxis

          3. Groups 1-4: Calculated creatinine clearance rate (CLCR) ≥ 80 ml/min/1.73m2 at baseline

          4. Group 5: CLCR ≥ 50 ml/min/1.73m2 at baseline

          5. Group 6: CLCR ≥ 20 ml/min/1.73m2 at baseline

        Key Exclusion Criteria:

          1. Known allergy/hypersensitivity to any β-lactam antibacterial

          2. History of clinically significant renal, hepatic, or hemodynamic instability

          3. Planned use of cardiopulmonary bypass or dialysis

          4. Planned blood transfusion within 24 hours of study drug administration

          5. Clinically significant abnormal laboratory test results not related to the underlying
             infection

          6. Receipt of piperacillin/tazobactam within 24 hours of study drug administration

          7. Likely to be at risk of hemodynamic disturbance following collection of the required
             PK blood samples
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <results_first_submitted>April 4, 2018</results_first_submitted>
  <results_first_submitted_qc>September 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2019</results_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02266706/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were screened for eligibility within 48 hours prior to study drug administration.</recruitment_details>
      <pre_assignment_details>After interim analysis, dose level adjustments were made to some groups based on safety and pharmacokinetics targets. Thus, the initial 6 cohorts were expanded to a total of 9 cohorts for analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
          <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
          <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
          <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
          <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
          <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
          <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
          <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
          <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="P9">
          <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
          <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrollment in another study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
          <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
          <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
          <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
          <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
          <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
          <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
          <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
          <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="B9">
          <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
          <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="1"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="2"/>
            <count group_id="B9" value="4"/>
            <count group_id="B10" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.1" spread="1.4"/>
                    <measurement group_id="B2" value="8.5" spread="1.2"/>
                    <measurement group_id="B3" value="5.5" spread="0.8"/>
                    <measurement group_id="B4" value="4.8" spread="1.8"/>
                    <measurement group_id="B5" value="0.9" spread="0.0"/>
                    <measurement group_id="B6" value="0.9" spread="0.7"/>
                    <measurement group_id="B7" value="0.1" spread="0.0"/>
                    <measurement group_id="B8" value="0.1" spread="0.0"/>
                    <measurement group_id="B9" value="0.2" spread="0.1"/>
                    <measurement group_id="B10" value="4.8" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Newborns (0-27days)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Infants and toddlers (28 days-23 months)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Children (2-11 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adolescents (12-17 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Ceftolozane</title>
        <description>Blood was collected for the determination of Cmax of ceftolozane. Cmax is expressed as geometric least-squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Ceftolozane</title>
          <description>Blood was collected for the determination of Cmax of ceftolozane. Cmax is expressed as geometric least-squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>μg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" lower_limit="50.2" upper_limit="80.4"/>
                    <measurement group_id="O2" value="56.2" lower_limit="45.3" upper_limit="69.7"/>
                    <measurement group_id="O3" value="51.4" lower_limit="37.9" upper_limit="69.7"/>
                    <measurement group_id="O4" value="96.6" lower_limit="71.2" upper_limit="131"/>
                    <measurement group_id="O5" value="50.5" lower_limit="29.8" upper_limit="85.6"/>
                    <measurement group_id="O6" value="91.3" lower_limit="72.1" upper_limit="116"/>
                    <measurement group_id="O7" value="45.0" lower_limit="36.3" upper_limit="55.9"/>
                    <measurement group_id="O8" value="34.9" lower_limit="24.1" upper_limit="50.7"/>
                    <measurement group_id="O9" value="45.2" lower_limit="33.3" upper_limit="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Tazobactam</title>
        <description>Blood was collected for the determination of Cmax of tazobactam. Cmax is expressed as geometric least-squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Tazobactam</title>
          <description>Blood was collected for the determination of Cmax of tazobactam. Cmax is expressed as geometric least-squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>μg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="8.59" upper_limit="22.9"/>
                    <measurement group_id="O2" value="9.25" lower_limit="5.92" upper_limit="14.5"/>
                    <measurement group_id="O3" value="15.7" lower_limit="8.36" upper_limit="29.6"/>
                    <measurement group_id="O4" value="24.8" lower_limit="13.2" upper_limit="46.6"/>
                    <measurement group_id="O5" value="11.6" lower_limit="3.88" upper_limit="34.7"/>
                    <measurement group_id="O6" value="22.4" lower_limit="13.8" upper_limit="36.6"/>
                    <measurement group_id="O7" value="11.7" lower_limit="7.48" upper_limit="18.3"/>
                    <measurement group_id="O8" value="6.87" lower_limit="3.17" upper_limit="14.9"/>
                    <measurement group_id="O9" value="12.1" lower_limit="6.43" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Ceftolozane</title>
        <description>Blood was collected for the determination of Tmax of ceftolozane.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Ceftolozane</title>
          <description>Blood was collected for the determination of Tmax of ceftolozane.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="1.00" upper_limit="1.10"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.58" upper_limit="1.13"/>
                    <measurement group_id="O3" value="1.02" lower_limit="1.02" upper_limit="1.03"/>
                    <measurement group_id="O4" value="1.03" lower_limit="1.03" upper_limit="1.12"/>
                    <measurement group_id="O5" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O6" value="1.05" lower_limit="0.58" upper_limit="1.95"/>
                    <measurement group_id="O7" value="1.08" lower_limit="0.95" upper_limit="1.90"/>
                    <measurement group_id="O8" value="1.80" lower_limit="1.03" upper_limit="2.57"/>
                    <measurement group_id="O9" value="1.07" lower_limit="1.07" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Tazobactam</title>
        <description>Blood was collected for the determination of Tmax of tazobactam.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Tazobactam</title>
          <description>Blood was collected for the determination of Tmax of tazobactam.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="1.10"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.58" upper_limit="1.13"/>
                    <measurement group_id="O3" value="1.02" lower_limit="1.02" upper_limit="1.03"/>
                    <measurement group_id="O4" value="1.03" lower_limit="1.03" upper_limit="1.12"/>
                    <measurement group_id="O5" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O6" value="1.05" lower_limit="0.58" upper_limit="1.95"/>
                    <measurement group_id="O7" value="1.08" lower_limit="0.95" upper_limit="1.33"/>
                    <measurement group_id="O8" value="3.89" lower_limit="1.03" upper_limit="6.75"/>
                    <measurement group_id="O9" value="1.07" lower_limit="1.07" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration at the Last Quantifiable Concentration (Clast) of Ceftolozane</title>
        <description>Blood was collected for the determination of Clast of ceftolozane. Clast is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration at the Last Quantifiable Concentration (Clast) of Ceftolozane</title>
          <description>Blood was collected for the determination of Clast of ceftolozane. Clast is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" spread="40.4"/>
                    <measurement group_id="O2" value="2.85" spread="37.3"/>
                    <measurement group_id="O3" value="2.47" spread="29.1"/>
                    <measurement group_id="O4" value="5.69" spread="59.5"/>
                    <measurement group_id="O5" value="2.53" spread="NA">Cannot be calculated for n=1</measurement>
                    <measurement group_id="O6" value="5.72" spread="96.1"/>
                    <measurement group_id="O7" value="8.70" spread="49.1"/>
                    <measurement group_id="O8" value="10.2" spread="49.2"/>
                    <measurement group_id="O9" value="6.26" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration at the Last Quantifiable Concentration (Clast) of Tazobactam</title>
        <description>Blood was collected for the determination of Clast of tazobactam. Clast is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration at the Last Quantifiable Concentration (Clast) of Tazobactam</title>
          <description>Blood was collected for the determination of Clast of tazobactam. Clast is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.232" spread="52.2"/>
                    <measurement group_id="O2" value="0.420" spread="188.6"/>
                    <measurement group_id="O3" value="0.137" spread="24.1"/>
                    <measurement group_id="O4" value="0.327" spread="62.7"/>
                    <measurement group_id="O5" value="0.224" spread="NA">Cannot be calculated for n=1</measurement>
                    <measurement group_id="O6" value="0.401" spread="90.5"/>
                    <measurement group_id="O7" value="0.657" spread="169.2"/>
                    <measurement group_id="O8" value="3.66" spread="57.6"/>
                    <measurement group_id="O9" value="0.266" spread="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Last Sampling Point (Tlast) of Ceftolozane</title>
        <description>Blood was collected for the determination of Tlast of ceftolozane.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Last Sampling Point (Tlast) of Ceftolozane</title>
          <description>Blood was collected for the determination of Tlast of ceftolozane.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="5.85" upper_limit="6.03"/>
                    <measurement group_id="O2" value="6.01" lower_limit="5.82" upper_limit="6.15"/>
                    <measurement group_id="O3" value="6.08" lower_limit="5.85" upper_limit="6.25"/>
                    <measurement group_id="O4" value="5.77" lower_limit="5.72" upper_limit="5.93"/>
                    <measurement group_id="O5" value="6.00" lower_limit="6.00" upper_limit="6.00"/>
                    <measurement group_id="O6" value="6.00" lower_limit="5.72" upper_limit="6.75"/>
                    <measurement group_id="O7" value="6.01" lower_limit="5.88" upper_limit="6.18"/>
                    <measurement group_id="O8" value="6.40" lower_limit="6.05" upper_limit="6.75"/>
                    <measurement group_id="O9" value="5.85" lower_limit="5.72" upper_limit="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Last Sampling Point (Tlast) of Tazobactam</title>
        <description>Blood was collected for the determination of Tlast of tazobactam.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Last Sampling Point (Tlast) of Tazobactam</title>
          <description>Blood was collected for the determination of Tlast of tazobactam.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3.10" lower_limit="2.02" upper_limit="4.15"/>
                    <measurement group_id="O3" value="5.85" lower_limit="4.03" upper_limit="6.08"/>
                    <measurement group_id="O4" value="5.72" lower_limit="3.85" upper_limit="5.93"/>
                    <measurement group_id="O5" value="4.00" lower_limit="4.00" upper_limit="4.00"/>
                    <measurement group_id="O6" value="5.02" lower_limit="4.02" upper_limit="5.75"/>
                    <measurement group_id="O7" value="5.95" lower_limit="2.18" upper_limit="6.10"/>
                    <measurement group_id="O8" value="6.40" lower_limit="6.05" upper_limit="6.75"/>
                    <measurement group_id="O9" value="5.85" lower_limit="5.72" upper_limit="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve (AUClast) of Ceftolozane</title>
        <description>Blood was collected for the determination of AUC from time zero to the last quantifiable concentration of ceftolozane. AUC0-last is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve (AUClast) of Ceftolozane</title>
          <description>Blood was collected for the determination of AUC from time zero to the last quantifiable concentration of ceftolozane. AUC0-last is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>Hours*μg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" lower_limit="103" upper_limit="150"/>
                    <measurement group_id="O2" value="102" lower_limit="86.2" upper_limit="121"/>
                    <measurement group_id="O3" value="94.2" lower_limit="74.1" upper_limit="120"/>
                    <measurement group_id="O4" value="172" lower_limit="135" upper_limit="219"/>
                    <measurement group_id="O5" value="98.8" lower_limit="65.1" upper_limit="150"/>
                    <measurement group_id="O6" value="178" lower_limit="148" upper_limit="214"/>
                    <measurement group_id="O7" value="131" lower_limit="111" upper_limit="155"/>
                    <measurement group_id="O8" value="118" lower_limit="88.2" upper_limit="159"/>
                    <measurement group_id="O9" value="119" lower_limit="93.7" upper_limit="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve (AUClast) of Tazobactam</title>
        <description>Blood was collected for the determination of AUC from time zero to the last quantifiable concentration of tazobactam. AUC0-last is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve (AUClast) of Tazobactam</title>
          <description>Blood was collected for the determination of AUC from time zero to the last quantifiable concentration of tazobactam. AUC0-last is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>Hours*μg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="10.7" upper_limit="27.9"/>
                    <measurement group_id="O2" value="9.69" lower_limit="6.27" upper_limit="15.0"/>
                    <measurement group_id="O3" value="17.6" lower_limit="9.53" upper_limit="32.7"/>
                    <measurement group_id="O4" value="28.5" lower_limit="15.4" upper_limit="52.8"/>
                    <measurement group_id="O5" value="14.8" lower_limit="5.08" upper_limit="42.9"/>
                    <measurement group_id="O6" value="28.9" lower_limit="18.0" upper_limit="46.6"/>
                    <measurement group_id="O7" value="21.3" lower_limit="13.8" upper_limit="33.0"/>
                    <measurement group_id="O8" value="21.6" lower_limit="10.2" upper_limit="45.9"/>
                    <measurement group_id="O9" value="21.9" lower_limit="11.8" upper_limit="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve (AUC0-inf) of Ceftolozane</title>
        <description>Blood was collected for the determination of AUC from time zero extrapolated to infinity of ceftolozane. AUC0-inf is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve (AUC0-inf) of Ceftolozane</title>
          <description>Blood was collected for the determination of AUC from time zero extrapolated to infinity of ceftolozane. AUC0-inf is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>Hours*μg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133" lower_limit="104" upper_limit="171"/>
                    <measurement group_id="O2" value="107" lower_limit="85.7" upper_limit="135"/>
                    <measurement group_id="O3" value="99.4" lower_limit="72.2" upper_limit="137"/>
                    <measurement group_id="O4" value="186" lower_limit="135" upper_limit="255"/>
                    <measurement group_id="O5" value="103" lower_limit="59.4" upper_limit="180"/>
                    <measurement group_id="O6" value="202" lower_limit="158" upper_limit="259"/>
                    <measurement group_id="O7" value="164" lower_limit="131" upper_limit="205"/>
                    <measurement group_id="O8" value="165" lower_limit="112" upper_limit="244"/>
                    <measurement group_id="O9" value="137" lower_limit="99.6" upper_limit="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve (AUC0-inf) of Tazobactam</title>
        <description>Blood was collected for the determination of AUC from time zero extrapolated to infinity of tazobactam. AUC0-inf is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve (AUC0-inf) of Tazobactam</title>
          <description>Blood was collected for the determination of AUC from time zero extrapolated to infinity of tazobactam. AUC0-inf is expressed as geometric least squares mean and confidence interval based on back-transformed least-squares mean and confidence interval from linear mixed-effects model with group fixed effect performed on natural log-transformed values.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>Hours*μg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="12.6" upper_limit="24.2"/>
                    <measurement group_id="O2" value="10.2" lower_limit="6.68" upper_limit="15.5"/>
                    <measurement group_id="O3" value="17.8" lower_limit="11.7" upper_limit="27.0"/>
                    <measurement group_id="O4" value="28.9" lower_limit="19.0" upper_limit="43.9"/>
                    <measurement group_id="O5" value="14.9" lower_limit="7.21" upper_limit="30.9"/>
                    <measurement group_id="O6" value="29.9" lower_limit="21.6" upper_limit="41.4"/>
                    <measurement group_id="O7" value="24.9" lower_limit="18.0" upper_limit="34.4"/>
                    <measurement group_id="O8" value="77.6" lower_limit="37.5" upper_limit="161"/>
                    <measurement group_id="O9" value="22.3" lower_limit="14.7" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Half-life (t1/2) of Ceftolozane</title>
        <description>Blood was collected for the determination of t1/2 of ceftolozane. t1/2 is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life (t1/2) of Ceftolozane</title>
          <description>Blood was collected for the determination of t1/2 of ceftolozane. t1/2 is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="16.7"/>
                    <measurement group_id="O2" value="1.29" spread="9.6"/>
                    <measurement group_id="O3" value="1.34" spread="14.0"/>
                    <measurement group_id="O4" value="1.48" spread="35.5"/>
                    <measurement group_id="O5" value="1.30" spread="NA">Cannot be calculated for n=1</measurement>
                    <measurement group_id="O6" value="1.63" spread="69.0"/>
                    <measurement group_id="O7" value="2.21" spread="37.6"/>
                    <measurement group_id="O8" value="3.14" spread="0.9"/>
                    <measurement group_id="O9" value="1.73" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Half-life (t1/2) of Tazobactam</title>
        <description>Blood was collected for the determination of t1/2 of tazobactam. t1/2 is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life (t1/2) of Tazobactam</title>
          <description>Blood was collected for the determination of t1/2 of tazobactam. t1/2 is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.702" spread="38.7"/>
                    <measurement group_id="O2" value="0.544" spread="3.1"/>
                    <measurement group_id="O3" value="0.719" spread="29.7"/>
                    <measurement group_id="O4" value="0.770" spread="34.2"/>
                    <measurement group_id="O5" value="0.538" spread="NA">Cannot be calculated for n=1</measurement>
                    <measurement group_id="O6" value="0.815" spread="85.1"/>
                    <measurement group_id="O7" value="1.09" spread="32.0"/>
                    <measurement group_id="O8" value="3.03" spread="NA">Cannot be calculated for n=1</measurement>
                    <measurement group_id="O9" value="0.875" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution at Steady State (Vss) of Ceftolozane</title>
        <description>Blood was collected for the determination of Vss of ceftolozane. Vss is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss) of Ceftolozane</title>
          <description>Blood was collected for the determination of Vss of ceftolozane. Vss is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>L/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.274" spread="25.7"/>
                    <measurement group_id="O2" value="0.296" spread="22.0"/>
                    <measurement group_id="O3" value="0.331" spread="15.6"/>
                    <measurement group_id="O4" value="0.312" spread="19.5"/>
                    <measurement group_id="O5" value="0.282" spread="NA">Cannot be calculated for n=1</measurement>
                    <measurement group_id="O6" value="0.340" spread="21.1"/>
                    <measurement group_id="O7" value="0.394" spread="12.6"/>
                    <measurement group_id="O8" value="0.344" spread="36.6"/>
                    <measurement group_id="O9" value="0.388" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution at Steady State (Vss) of Tazobactam</title>
        <description>Blood was collected for the determination of Vss of tazobactam. Vss is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss) of Tazobactam</title>
          <description>Blood was collected for the determination of Vss of tazobactam. Vss is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>L/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.474" spread="69.6"/>
                    <measurement group_id="O2" value="0.740" spread="30.2"/>
                    <measurement group_id="O3" value="0.488" spread="32.0"/>
                    <measurement group_id="O4" value="0.513" spread="49.2"/>
                    <measurement group_id="O5" value="0.421" spread="NA">Cannot be calculated for n=1</measurement>
                    <measurement group_id="O6" value="0.574" spread="36.2"/>
                    <measurement group_id="O7" value="0.668" spread="19.8"/>
                    <measurement group_id="O8" value="0.338" spread="NA">Cannot be calculated for n=1</measurement>
                    <measurement group_id="O9" value="0.667" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Clearance (CL) of Ceftolozane</title>
        <description>Blood was collected for the determination of CL of ceftolozane. CL is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Clearance (CL) of Ceftolozane</title>
          <description>Blood was collected for the determination of CL of ceftolozane. CL is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>L/hour/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.146" spread="27.0"/>
                    <measurement group_id="O2" value="0.168" spread="21.3"/>
                    <measurement group_id="O3" value="0.181" spread="3.8"/>
                    <measurement group_id="O4" value="0.162" spread="31.1"/>
                    <measurement group_id="O5" value="0.176" spread="NA">Cannot be calculated for n=1</measurement>
                    <measurement group_id="O6" value="0.149" spread="43.2"/>
                    <measurement group_id="O7" value="0.118" spread="36.0"/>
                    <measurement group_id="O8" value="0.0723" spread="32.2"/>
                    <measurement group_id="O9" value="0.147" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Clearance (CL) of Tazobactam</title>
        <description>Blood was collected for the determination of CL of tazobactam. CL is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
        <time_frame>Predose and 0.5, 1, 2, 4, and 6 hours after the start of infusion for Cohorts 1 to 4 and 1, 2, and 6 hours after start of infusion for Cohorts 5 and 6.</time_frame>
        <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Clearance (CL) of Tazobactam</title>
          <description>Blood was collected for the determination of CL of tazobactam. CL is expressed as geometric mean and percent geometric coefficient of variation, CV% = 100*sqrt(exp(s^2)-1), where s^2 is the observed between-subjects variance on the natural log-scale.</description>
          <population>The pharmacokinetics population included enrolled participants who received a full dose of study drug and had blood samples with quantifiable plasma levels at Cmax and at least 2 time points after Cmax, and were evaluable for the outcome measure.</population>
          <units>L/hour/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.556" spread="53.9"/>
                    <measurement group_id="O2" value="0.886" spread="23.1"/>
                    <measurement group_id="O3" value="0.506" spread="42.0"/>
                    <measurement group_id="O4" value="0.519" spread="44.8"/>
                    <measurement group_id="O5" value="0.611" spread="NA">Cannot be calculated for n=1</measurement>
                    <measurement group_id="O6" value="0.502" spread="34.7"/>
                    <measurement group_id="O7" value="0.385" spread="34.1"/>
                    <measurement group_id="O8" value="0.0760" spread="NA">Cannot be calculated for n=1</measurement>
                    <measurement group_id="O9" value="0.452" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With One or More Adverse Events</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
        <time_frame>Up to Day 10</time_frame>
        <population>The safety population was all enrolled participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Adverse Events</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
          <population>The safety population was all enrolled participants who received study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued the Study Due to an Adverse Event</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
        <time_frame>Up to Day 10</time_frame>
        <population>The safety population was all enrolled participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
            <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
            <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
            <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued the Study Due to an Adverse Event</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.</description>
          <population>The safety population was all enrolled participants who received study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 10</time_frame>
      <desc>The safety population was all enrolled participants who received study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: ≥12 to &lt;18 Years TOL/TAZ 1000/500 mg FDC</title>
          <description>Participants ≥12 to &lt;18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: ≥7 to &lt;12 Years TOL/TAZ 18/9 mg/kg</title>
          <description>Participants ≥7 to &lt;12 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 18/9 mg/kg</title>
          <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 3: ≥2 to &lt;7 Years TOL/TAZ 30/15 mg/kg</title>
          <description>Participants ≥2 to &lt;7 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 18/9 mg/kg</title>
          <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 18/9 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 4: ≥3 Months to &lt;2 Years TOL/TAZ 30/15 mg/kg</title>
          <description>Participants ≥3 months to &lt;2 years of age received a single dose of ceftolozane/tazobactam 30/15 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 5: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
          <description>Participants from birth (&gt;32 weeks gestation, 7 days postnatal) to &lt;3 months of age received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 12/6 mg/kg</title>
          <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance of 20 - 49 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 12/6 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
        <group group_id="E9">
          <title>Cohort 6: Birth to &lt;3 Months TOL/TAZ 20/10 mg/kg</title>
          <description>Participants from birth (≤32 weeks gestation, 7 days postnatal) to &lt;3 months of age with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of ceftolozane/tazobactam 20/10 mg/kg as a 60-minute infusion on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Weaning failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Waist circumference increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The data generated in this clinical study are the exclusive property of the Sponsor and are confidential. The Sponsor will make all reasonable efforts to publish the results of the study in an appropriate peer-reviewed journal. Authorship on the primary publication of the results from this study will be based on contributions to study design, enrollment, data analysis, and interpretation of results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

